NetworkNewsBreaks Archive - Page 2244 of 2282

ThursdayJan 12, 2017 2:16 pm

NetworkNewsBreaks – Transgenomic, Inc. (NASDAQ: TBIO) Shares Skyrocket on Licensing Deal with LifeLabs for ICE COLD-PCR, Canadian Patent Allowance

Shares of Transgenomic (NASDAQ: TBIO) are up roughly 169% late morning on word of its licensing agreement with Canadian laboratory service provider LifeLabs, which will use Transgenomics’ ICE COLD-PCR (ICP) technology as its mutation enrichment platform for cancer testing. The three-year renewable agreement permits LifeLabs to benefit from technology improvements and additional product launches during its term. Separately, Transgenomic also announced issuance of a new Canadian patent for ICP which covers the use of the ICE COLD-PCR method that enriches mutated DNA sequences in a background of normal DNA through to 2030. “We believe that this sizable commercial licensing agreement…

ThursdayJan 12, 2017 2:13 pm

NetworkNewsBreaks – BioLargo, Inc. (BLGO) on Cusp of Commercial Betas of AOS Filter System

BioLargo (OTCQB: BLGO) is a science and technology company that, for the last decade, has continued to innovate sustainable, disruptive technology-based science products designed to help solve problems threatening the world’s supply of water, food, agriculture, health care and energy. As an “invention” company, BioLargo and its subsidiaries deliver impactful products and services featuring BioLargo® Technology for both regulated and unregulated uses and applications. Last fall, the company announced the completion of the alpha unit of its advanced water treatment system - the AOS Filter (advanced oxidation system) – for applications ranging from food and agriculture to ballast water treatment.…

WednesdayJan 11, 2017 3:41 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 11, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: GRSO 37.44% – News: Releases shareholder update CTXR 27.67% – News: Mino-Lok™ treatment addresses antibiotic resistant pathogens VPRB 21.89% – News: Launched product with Kush Army Knives, LLC WTXR 16.67% – News: Formed WTXR Operating (Texas) Inc. subsidiary NMUS 16.44% – News: Signed licensing agreement with the University of Mississippi TWOH 7.78% – News: Launched marketing campaign for Two Hands application CYDY 6.19% – News: Requested Breakthrough Therapy Designation from the FDA for PRO…

WednesdayJan 11, 2017 3:41 pm

NetworkNewsBreaks – Intellipharmaceutics International, Inc. (NASDAQ: IPCI) Forecasts Improved Annual Sales on Launch of Generic Focalin XR®

Intellipharmaceutics’ (NASDAQ: IPCI) is uniquely positioned to operate in the niche market created by the expiration of drug product patents and exclusivity periods. Part of the company’s strategy includes formulating generic products that are bioequivalent to products covered by soon-to-expire or already expired patents. Intellipharmaceutics recently announced that its marketing partner, Par Pharmaceutical (“Par”), has launched its generic Focalin XR® capsules in 25 and 35 mg strengths in the United States. The FDA has approved Par’s abbreviated new drug application (“ANDA”) for its generic Focalin XR capsules in the 5, 10, 15, 20, 25, 30, 35 and 40 mg strengths. As…

WednesdayJan 11, 2017 3:33 pm

NetworkNewsBreaks – Guitammer (GTMM) Reports 475% Increase in FY2016 ButtKicker® Sales; Says 2017 Will Be Even Better

Reporting a triple-digit sales increase of its ButtKicker®-equipped cinema seats for full-year 2016, The Guitammer Company (OTCQB: GTMM) forecasts that its performance in 2017 will be even stronger. The Ohio-based company yesterday said it sold over 11,300 new ButtKicker®-equipped cinema seats for 57 new auditoriums in 2016, marking a 475% increase compared to 12 auditoriums and over 2,500 seats in 2015. There are now more than 20,000 ButtKicker-enabled seats in over 105 cinema auditoriums worldwide. The company also guided for continued growth this year, and said it expects to ship ButtKicker products for 1,000 seats in five new auditoriums by…

WednesdayJan 11, 2017 3:26 pm

NetworkNewsBreaks – Petrogas (PTCO) Shares Climb on Acquisition of Fractional Interest in Texas

Shares of Petrogas Company (OTC: PTCO) are up 9% after the company said it has acquired a fractional interest in 11 oil and gas wells operated by Vanguard Operating (NASDAQ: VNR) in Cherokee County, Texas. Only some of the wells are currently producing hydrocarbons. "This is the type of acquisition we love to make as most of these wells had their production turned off in 2014 when oil prices began sliding. Now that prices are coming back to profitable levels, we expect that all offline wells could be brought back to production with minimal effort over the coming months," Petrogas…

WednesdayJan 11, 2017 2:38 pm

NetworkNewsBreaks – Ironclad Performance Wear (ICPW) Strategizes to Buck Impact of Oil & Gas Uncertainties

Ironclad Performance Wear (OTCQB: ICPW) designs and manufactures work wear for various construction, do-it-yourself, industrial, sporting goods, and general services markets – a focus that generated third quarter 2016 sales of $6.45 million, up 19.1% year-over-year. The company specializes in task-specific gloves, such as the KONG® original, which was co-developed by the oil and gas industry safety committee for use in oil and gas drilling, extraction and refining, fracking, and many other construction-related fields. On the same note, Ironclad is hedging itself against struggles of the current oil and gas market, focusing on expansion in other key segments. To learn…

WednesdayJan 11, 2017 2:30 pm

NetworkNewsBreaks – Sangamo Therapeutics, Inc. (NASDAQ: SGMO): FDA Grants Orphan Drug Designation for SB-318

Sangamo Therapeutics (NASDAQ: SGMO) is trading higher this morning on news the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s SB-318, a genome editing product candidate for the treatment of Mucopolysaccharidosis Type I (MPS I), a rare lysosomal storage disorder. The FDA grants orphan drug designation to drugs and biologics intended to treat rare diseases, providing incentives to advance development of rare disease drugs as well as commercialization of drugs that progress to approval. Sangamo also noted its plans to “conduct the first ever in vivo genome editing clinical trials including Phase 1/2 studies…

TuesdayJan 10, 2017 3:01 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 10, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: DSGT 75.00% – News: Presenting product line at 2017 PGA Merchandise Show in Orlando XGTI 17.31% – News: Regains Nasdaq listing compliance CMXC 16.67% – News: Reports positive observational results of trial in Manila, Philippines KAYS 16.49% – News: Receives full recreational marijuana retailer license from OLCC for South Salem Kaya Shack™; secures $2.1M funding commitment HPCQ 15.00% – News: Enters exclusive distributor agreement for Guatemala with Fertica Group TENG 14.75%– News: Advisement from…

TuesdayJan 10, 2017 3:01 pm

NetworkNewsBreaks – Biocept, Inc. (NASDAQ: BIOC) Shares Surge on Coverage Agreement with Blue Cross Blue Shield of Texas

Shares of Biocept (NASDAQ: BIOC) are up 15% on word the molecular diagnostics company has obtained an in-network provider agreement with Blue Cross Blue Shield of Texas (BCBSTX). The company views the achievement as a milestone in expanding coverage for its Target Selector™ platform, as BCBSTX is the largest provider of health benefits in Texas. "Partnering with health insurers is a major focus of our business strategy, as it may increase physician access to this non-invasive technology for their patients and provide timely adjudication of claims for patients. Securing this in-network agreement is an important milestone for Biocept, as Texas…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks